Healthy volunteers help uncover drug interactions for FA treatment

NCT ID NCT07149415

Completed Knowledge-focused Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study in 22 healthy volunteers looked at whether omaveloxolone (a drug for Friedreich's ataxia) changes how the body processes omeprazole (a common stomach acid reducer). Participants took omeprazole alone and then together with omaveloxolone over 17 days. Researchers measured drug levels in the blood and monitored safety to understand any interactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omaveloxolone (also known as BIIB141 or SKYCLARYS) and omeprazole
What this could lead to: If successful, this study could help doctors understand how to safely prescribe omaveloxolone with other common drugs like omeprazole.
What could go wrong: This is a small, early-phase study in healthy people, not patients. It only looks at drug interactions, not whether the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Show contact details

Locations

Austin Clinical Research Unit

Austin, Texas, 78744, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.